JP7822954B2 - ダリドレキサントの医学的用途 - Google Patents

ダリドレキサントの医学的用途

Info

Publication number
JP7822954B2
JP7822954B2 JP2022563036A JP2022563036A JP7822954B2 JP 7822954 B2 JP7822954 B2 JP 7822954B2 JP 2022563036 A JP2022563036 A JP 2022563036A JP 2022563036 A JP2022563036 A JP 2022563036A JP 7822954 B2 JP7822954 B2 JP 7822954B2
Authority
JP
Japan
Prior art keywords
sleep
daridorexant
daytime
therapeutic agent
insomnia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022563036A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521492A (ja
JP2023521492A5 (https=
Inventor
ブラウンシュタイン ガイ
パイン スコット
セボーク－キンター ダルマ
ヴァイラント セドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of JP2023521492A publication Critical patent/JP2023521492A/ja
Publication of JP2023521492A5 publication Critical patent/JP2023521492A5/ja
Application granted granted Critical
Publication of JP7822954B2 publication Critical patent/JP7822954B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022563036A 2020-04-19 2021-04-16 ダリドレキサントの医学的用途 Active JP7822954B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2020060940 2020-04-19
EPPCT/EP2020/060940 2020-04-19
PCT/EP2021/059943 WO2021213923A1 (en) 2020-04-19 2021-04-16 Medical use of daridorexant

Publications (3)

Publication Number Publication Date
JP2023521492A JP2023521492A (ja) 2023-05-24
JP2023521492A5 JP2023521492A5 (https=) 2024-04-25
JP7822954B2 true JP7822954B2 (ja) 2026-03-03

Family

ID=75478068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563036A Active JP7822954B2 (ja) 2020-04-19 2021-04-16 ダリドレキサントの医学的用途

Country Status (14)

Country Link
US (1) US20230134935A1 (https=)
EP (1) EP4138822A1 (https=)
JP (1) JP7822954B2 (https=)
KR (1) KR20230004670A (https=)
CN (1) CN115427037A (https=)
AU (1) AU2021260018A1 (https=)
BR (1) BR112022020924A2 (https=)
CA (1) CA3175369A1 (https=)
CL (1) CL2022002855A1 (https=)
IL (1) IL297234A (https=)
MX (1) MX2022011179A (https=)
PH (1) PH12022552763A1 (https=)
TW (1) TW202200133A (https=)
WO (1) WO2021213923A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
WO2024019978A2 (en) * 2022-07-19 2024-01-25 Rutgers, The State University Of New Jersey Therapeutic combinations and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502447A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
JP2016539136A (ja) 2013-12-03 2016-12-15 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ （ｓ）−（２−（６−クロロ−７−メチル−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−２−メチルピロリジン−１−イル）（５−メトキシ−２−（２ｈ−１，２，３−トリアゾール−２−イル）フェニル）メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用
JP2016539157A (ja) 2013-12-04 2016-12-15 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ベンゾイミダゾール−プロリン誘導体の使用
JP2017531683A (ja) 2014-10-23 2017-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
LT3619199T (lt) 2017-05-03 2021-09-27 Idorsia Pharmaceuticals Ltd 2-([1,2,3]triazol-2-il)-benzenkarboksirūgšties darinių gamyba

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502447A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
JP2016539136A (ja) 2013-12-03 2016-12-15 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ （ｓ）−（２−（６−クロロ−７−メチル−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−２−メチルピロリジン−１−イル）（５−メトキシ−２−（２ｈ−１，２，３−トリアゾール−２−イル）フェニル）メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用
JP2016539157A (ja) 2013-12-04 2016-12-15 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ベンゾイミダゾール−プロリン誘導体の使用
JP2017531683A (ja) 2014-10-23 2017-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANN NEUROL，2020年02月05日，Vol.87，pp.347-356

Also Published As

Publication number Publication date
CA3175369A1 (en) 2021-10-28
TW202200133A (zh) 2022-01-01
JP2023521492A (ja) 2023-05-24
BR112022020924A2 (pt) 2023-02-14
AU2021260018A1 (en) 2022-12-22
MX2022011179A (es) 2022-10-07
WO2021213923A1 (en) 2021-10-28
KR20230004670A (ko) 2023-01-06
IL297234A (en) 2022-12-01
US20230134935A1 (en) 2023-05-04
EP4138822A1 (en) 2023-03-01
CL2022002855A1 (es) 2023-06-02
CN115427037A (zh) 2022-12-02
PH12022552763A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
Roth et al. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia
US20060122127A1 (en) Methods for reducing the side effects associated with mirtzapine treatment
JP2003506483A (ja) シクロベンザプリンおよびその組成物による全般性不安障害の処置
TW200403997A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US12485100B2 (en) Treatment of menstrual cycle-induced symptoms
JP7822954B2 (ja) ダリドレキサントの医学的用途
WO2021140103A1 (en) Cognitive disorder prevention and therapy
CN111447971A (zh) 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
Winkelman et al. Current patterns and future directions in the treatment of insomnia
US20230115839A1 (en) Methods For Treating Hypersomnia
TW201211021A (en) Methods of use of cyclic amide derivatives to treat schizophrenia
EA051128B1 (ru) Медицинское применение даридорексанта
Brown et al. Psychiatric disorders
US20230381168A1 (en) Adjunctive therapy for depression
HK40075517B (en) Treatment of menstrual cycle-induced symptoms
HK40075517A (en) Treatment of menstrual cycle-induced symptoms
Kalko et al. Potential risk and pharmacological safety features of hypnotics. Music therapy as a non-drug way to improve sleep quality
HK40112834A (zh) 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗
Rutkofsky et al. Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review
CN120051276A (zh) 减少对神经精神病学治疗的身体依赖性的方法
EA049139B1 (ru) Лечение симптомов, вызванных менструальным циклом
US20230381169A1 (en) Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist
BRALEY et al. Sleeptions among persons with comorbidmultiple sclero-condi
Lippmann et al. Problems with sleep: What should the doctor do?
REINEMER APPROVED BY THE GRADUATE COUNCIL, COLLEGE^ PF—DENTISTRY:(signed) _ f Assistant Dean of Research and Advanced Education APPROVED BY THE GRADUATE COUNCIL

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250422

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260218